First Republic Investment Management Inc. increased its holdings in shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) by 4.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 432,093 shares of the specialty pharmaceutical company’s stock after buying an additional 16,891 shares during the quarter. First Republic Investment Management Inc. owned 0.12% of Valeant Pharmaceuticals Intl worth $6,879,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also made changes to their positions in the company. Bank of New York Mellon Corp grew its stake in Valeant Pharmaceuticals Intl by 2.2% during the 4th quarter. Bank of New York Mellon Corp now owns 359,894 shares of the specialty pharmaceutical company’s stock worth $7,479,000 after buying an additional 7,683 shares during the last quarter. Cetera Investment Advisers purchased a new position in Valeant Pharmaceuticals Intl during the 4th quarter worth $208,000. Quadrant Private Wealth Management LLC purchased a new position in Valeant Pharmaceuticals Intl during the 4th quarter worth $357,000. Kovack Advisors Inc. purchased a new position in Valeant Pharmaceuticals Intl during the 4th quarter worth $405,000. Finally, Gabelli Funds LLC grew its stake in Valeant Pharmaceuticals Intl by 24.2% during the 4th quarter. Gabelli Funds LLC now owns 113,088 shares of the specialty pharmaceutical company’s stock worth $2,350,000 after buying an additional 22,000 shares during the last quarter. Hedge funds and other institutional investors own 50.13% of the company’s stock.
Get Valeant Pharmaceuticals Intl alerts:Shares of Valeant Pharmaceuticals Intl opened at $22.24 on Tuesday, MarketBeat.com reports. The stock has a market capitalization of $7.77 billion, a PE ratio of 5.62, a P/E/G ratio of 0.44 and a beta of -0.35. Valeant Pharmaceuticals Intl Inc has a 52-week low of $10.94 and a 52-week high of $24.43. The company has a quick ratio of 0.92, a current ratio of 1.18 and a debt-to-equity ratio of 5.59.
Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last released its quarterly earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported $0.89 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.29. The company had revenue of $2 billion during the quarter, compared to analysts’ expectations of $1.95 billion. Valeant Pharmaceuticals Intl had a positive return on equity of 27.87% and a negative net margin of 10.65%. Valeant Pharmaceuticals Intl’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.79 EPS. equities research analysts expect that Valeant Pharmaceuticals Intl Inc will post 3.33 earnings per share for the current fiscal year.
Several brokerages recently weighed in on VRX. Jefferies Group boosted their target price on Valeant Pharmaceuticals Intl to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, May 9th. HC Wainwright reaffirmed a “hold” rating and set a $16.00 price target on shares of Valeant Pharmaceuticals Intl in a research report on Monday, May 7th. Cantor Fitzgerald set a $25.00 price target on Valeant Pharmaceuticals Intl and gave the stock a “buy” rating in a research report on Tuesday, May 8th. BTIG Research reaffirmed a “hold” rating on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, May 9th. Finally, Piper Jaffray Companies set a $13.00 price target on Valeant Pharmaceuticals Intl and gave the stock a “sell” rating in a research report on Wednesday, May 9th. Five investment analysts have rated the stock with a sell rating, ten have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Valeant Pharmaceuticals Intl has an average rating of “Hold” and a consensus target price of $19.26.
In other news, Director Schutter Richard U. De acquired 15,000 shares of the business’s stock in a transaction on Tuesday, May 15th. The stock was bought at an average cost of $21.83 per share, for a total transaction of $327,450.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Schutter Richard U. De acquired 10,000 shares of the business’s stock in a transaction on Thursday, March 8th. The shares were purchased at an average price of $15.34 per share, with a total value of $153,400.00. Following the completion of the purchase, the director now owns 106,062 shares in the company, valued at approximately $1,626,991.08. The disclosure for this purchase can be found here. Insiders purchased a total of 7,136,629 shares of company stock valued at $110,029,937 in the last ninety days. 11.54% of the stock is currently owned by insiders.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.
No comments:
Post a Comment